background
experiment
studi
viral
infect
shown
induc
type
inflamm
asthmat
whether
featur
natur
occur
virusinduc
asthma
exacerb
unknown
thymic
stromal
lymphopoietin
tslp
releas
airway
epithelium
respons
damag
suggest
link
viral
infect
type
inflamm
role
tslp
asthma
exacerb
unknown
object
assess
whether
type
inflamm
measur
sputum
eosinophil
fraction
exhal
nitric
oxid
feno
featur
natur
occur
virusinduc
exacerb
asthma
whether
tslp
associ
type
inflamm
method
patient
present
hospit
acut
asthma
examin
exacerb
week
recoveri
assess
includ
spirometri
feno
induc
sputum
differenti
count
tslp
mrna
level
nasal
swab
collect
viral
detect
result
sputum
eosinophil
feno
similar
virusposit
n
neg
patient
n
virusposit
patient
tslp
express
lower
exacerb
followup
p
high
tslp
exacerb
associ
lower
sputum
eosinophil
p
higher
p
virusposit
patient
predict
neg
correl
feno
sputum
eosinophil
p
p
respect
conclus
find
support
type
inflamm
present
patient
virusinduc
asthma
exacerb
degre
nonvir
exacerb
correl
neg
howev
virusposit
patient
high
tslp
express
exacerb
associ
low
sputum
eosinophil
suggest
effect
tslp
vivo
set
asthma
exacerb
might
differ
type
induc
effect
observ
experiment
studi
estim
preval
nearli
asthma
one
frequent
chronic
diseas
western
countri
exacerb
major
caus
morbid
health
care
util
respiratori
virus
one
common
trigger
asthma
exacerb
underli
mechan
fulli
understood
overal
around
half
asthma
patient
promin
type
inflamm
stabl
diseas
character
driven
eosinophilia
sputum
blood
mucu
hypersecret
airway
hyperrespons
increas
ige
product
driven
phenotyp
associ
sever
diseas
increas
risk
exacerb
whether
aggrav
type
inflamm
featur
virusinduc
nonvir
exacerb
current
unknown
like
implic
efficaci
emerg
biolog
treatment
reduc
rate
sever
exacerb
allergen
sensit
exposur
establish
caus
increas
type
inflamm
howev
vitro
studi
suggest
respiratori
virus
capabl
independ
induc
type
inflamm
caus
releas
proinflammatori
cytokin
includ
thymic
stromal
lymphopoietin
tslp
airway
epithelium
innat
immun
pathway
tslp
caus
releas
type
cytokin
tcell
activ
dendrit
cell
direct
action
innat
lymphoid
cell
ilc
tslp
increas
patient
asthma
compar
control
antitslp
antibodi
shown
reduc
airway
inflamm
respons
allergen
provoc
test
epitheli
cell
asthmat
seem
particular
prone
tslp
releas
follow
exposur
viral
infect
vitro
whether
tslp
induc
asthmat
viral
infect
vivo
stimul
type
inflamm
unknown
asthma
patient
particularli
type
inflamm
experi
sever
symptom
experiment
infect
respiratori
virus
although
controversi
mechan
propos
involv
reduc
product
interferon
whether
patient
high
type
inflamm
reallif
viral
infect
experi
sever
exacerb
unclear
aim
present
studi
test
hypothesi
sputum
eosinophilia
increas
feno
featur
natur
occur
virusinduc
exacerb
secondarili
level
sputum
eosinophilia
feno
associ
degre
tslp
express
sputum
final
wish
test
whether
type
inflamm
virusinduc
exacerb
would
associ
sever
exacerb
measur
exploratori
outcom
includ
rhinoviru
subtyp
system
marker
inflamm
studi
prospect
observ
studi
conduct
bispebjerg
univers
hospit
juli
septemb
patient
recruit
hospit
emerg
depart
acut
asthma
clinic
within
hospit
research
unit
seen
within
h
contact
exacerb
defin
worsen
symptom
surpass
daili
variat
requir
chang
treatment
line
ersat
recommend
week
particip
reexamin
research
unit
patient
doctor
diagnosi
asthma
diagnosi
confirm
studi
line
gina
recommend
patient
year
age
pregnant
women
patient
pulmonari
diseas
asthma
exclud
current
past
smoker
includ
studi
approv
local
scientif
ethic
committe
protocol
nr
fraction
expiratori
nitric
oxid
feno
nioxminor
aerocrin
sweden
assess
follow
recommend
er
at
use
mean
two
measur
patient
complet
spirometri
easyon
ndd
switzerland
accord
er
guidelin
use
nhane
iii
lung
function
predict
valu
patient
examin
exacerb
ask
withhold
prior
spirometri
time
sinc
last
dose
reliev
taken
record
induc
sputum
process
describ
pavord
et
al
brief
inhal
mg
terbutalin
sputum
induc
inhal
hyperton
salin
increas
concentr
min
total
durat
min
sputum
plug
select
process
cytospin
prepar
differenti
cell
count
nonsquam
cell
complet
hospit
clinic
laboratori
complet
full
white
blood
cell
differenti
count
measur
highsensit
creactiv
protein
hscrp
total
ige
specif
ige
common
allergen
grass
hous
dust
mite
birch
mugwort
dog
cat
hors
cladosporium
herbarum
alternaria
tenui
atopi
defin
presenc
specif
ige
iuml
one
allergen
asthma
control
assess
asthma
control
questionnair
acq
flock
nasal
swab
copan
itali
use
sampl
turbin
nasal
sampl
assess
human
adenoviru
speci
bd
human
bocaviru
coronavirus
influenza
virus
b
c
parainfluenzavirus
ki
wu
polyomavirus
respiratori
syncyti
viru
type
b
human
metapneumoviru
use
tandem
multiplex
realtim
pcr
assay
pcr
direct
picornaviru
sequenc
utr
use
detect
rv
product
identifi
speci
level
rva
rvb
rvc
sequenc
bp
product
analys
use
clustalx
softwar
local
hospit
laboratori
bispebjerg
hospit
complet
bacteri
cultur
spontan
expector
collect
exacerb
sputum
cell
pellet
store
rnalat
ambion
usa
kept
c
process
rneasi
mini
kit
invitrogen
usa
use
extract
mrna
follow
manufactur
recommend
rna
extract
cdna
synthesis
use
ssiii
revers
transcriptas
invitrogen
usa
describ
manufactur
tslp
quantifi
use
digit
droplet
pcr
biorad
usa
taqman
primer
and
probe
gapdh
use
normal
analys
particip
divid
tslp
high
tslp
low
median
express
data
analys
spss
version
ibm
spss
usa
normal
distribut
data
report
mean
standard
deviat
analys
use
student
ttest
continu
variabl
chisquar
test
categor
variabl
logtransform
variabl
report
geometr
mean
gm
ci
logtransform
sputum
eosinophil
percentag
case
set
prior
transform
nonnorm
distribut
data
report
median
rang
comparison
made
use
mannwhitney
utest
regard
tslp
use
median
express
classifi
patient
either
tslphigh
median
tslplow
median
exacerb
multipl
linear
regress
model
stratifi
viru
detect
use
examin
determin
predict
time
exacerb
due
multicollinear
inflammatori
marker
assess
separ
adjust
predefin
covari
gender
age
smoke
bacteri
infect
ic
usag
analys
pvalu
consid
signific
total
patient
includ
studi
detect
respiratori
viru
exacerb
virus
detect
rhinoviru
human
coronaviru
parainfluenza
viru
human
metapneumoviru
fig
among
patient
respiratori
viru
six
bacteri
coinfect
h
influenza
pneumonia
aureu
catarrhali
three
patient
bacteri
infect
virusneg
group
pneumonia
gemella
haemolysan
p
comparison
virusposit
neg
group
nine
patient
bacteri
infect
includ
conclus
remain
unchang
patient
bacteri
infect
exclud
analys
demograph
patient
without
viral
infect
similar
level
treatment
requir
exacerb
tabl
likewis
lung
function
inflammatori
marker
larg
similar
except
higher
crp
virusposit
group
gm
ci
p
compar
virusneg
group
gm
ci
sputum
induct
success
patient
without
viru
viru
absolut
number
eosinophil
neutrophil
higher
virusposit
patient
compar
virusneg
patient
percentag
cell
type
differ
virusposit
neg
tabl
consequ
distribut
patient
establish
sputum
phenotyp
similar
viral
nonvir
exacerb
fig
virusinduc
group
feno
higher
exacerb
gm
ci
p
compar
followup
gm
ci
also
case
nonvir
group
gm
ci
vs
ci
respect
p
sputum
eosinophil
significantli
differ
followup
compar
percentag
exacerb
either
group
period
initi
followup
visit
patient
treat
follow
clinic
guidelin
gina
follow
admiss
receiv
oral
cours
prednisolon
mg
daili
day
rest
manag
increas
inhal
steroid
treatment
initi
studi
team
exist
treatment
laba
leukotrien
asthma
medic
continu
follow
exacerb
signific
differ
clinic
manag
virusposit
virusneg
group
differ
sputum
tslp
mrna
express
patient
without
viral
infect
exacerb
gm
ci
vs
ci
respect
p
fig
fig
patient
without
viru
infect
differ
inflammatori
phenotyp
acq
high
low
tslp
express
n
n
respect
fig
howev
virusposit
patient
high
tslp
express
level
n
significantli
lower
sputum
eosinophil
percentag
gm
ci
p
vs
ci
higher
p
vs
lower
acq
score
p
vs
higher
blood
neutrophil
median
cellsl
rang
p
vs
cellsl
trend
lower
feno
gm
ppb
ci
p
vs
ppb
ci
compar
low
tslp
express
level
n
fig
differ
ic
usag
tslp
high
low
group
examin
impact
type
inflamm
clinic
sever
exacerb
associ
sputum
eosinophil
feno
exacerb
examin
virusposit
neg
group
percentag
sputum
eosinophil
correl
neg
patient
viru
detect
exacerb
rho
p
patient
nonvir
exacerb
rho
p
adjust
gender
age
smoke
statu
bacteri
infect
ic
usag
multipl
linear
regress
associ
remain
signific
p
p
respect
tabl
univari
analys
feno
neg
correl
virusposit
group
rho
p
significantli
associ
virusneg
patient
rho
p
adjust
potenti
confound
associ
remain
signific
virusposit
group
p
yet
virusneg
group
p
tabl
exploratori
predictor
also
measur
blood
eosinophil
total
ige
sputum
neutrophil
use
analysi
blood
eosinophil
total
ige
associ
differ
virusposit
neg
patient
sputum
neutrophil
associ
either
group
data
shown
patient
infect
rhinoviru
lower
predict
exacerb
p
compar
patient
respiratori
virus
higher
acq
score
p
vs
respect
tabl
signific
differ
demograph
spirometri
inflammatori
marker
patient
infect
rvc
n
compar
patient
infect
rva
n
tabl
studi
type
inflamm
tslp
mrna
express
present
virusinduc
exacerb
similar
extent
nonvir
exacerb
furthermor
sputum
eosinophil
feno
neg
correl
exacerb
knowledg
first
report
tslp
mrna
express
natur
occur
asthma
exacerb
contrast
hypothesi
found
particip
high
sputum
tslp
lower
sputum
eosinophil
lower
feno
higher
exacerb
particip
low
sputum
tslp
suggest
tslp
promot
type
inflamm
airway
virusinduc
exacerb
asthma
possibl
time
sampl
collect
chang
posttransl
modif
tslp
mrna
could
impact
final
amount
tslp
protein
produc
although
previou
studi
found
good
concord
tslp
gene
express
protein
concentr
inhibitori
effect
corticosteroid
rule
would
explain
differ
virusposit
virusneg
group
although
ex
vivo
studi
propos
tslp
act
mediat
eosinophilia
respons
viral
infect
document
vivo
find
suggest
effect
might
complex
set
asthma
exacerb
suggest
pathway
eg
modul
innat
immun
system
contribut
initi
type
inflamm
respons
viral
infect
attempt
measur
tslp
protein
use
highli
sensit
elisa
bioplex
pro
biorad
luminex
platform
lower
limit
detect
pgml
detect
tslp
sampl
may
due
addit
dithiothreitol
dtt
sputum
sampl
part
standard
method
sputum
sampl
process
sinc
dtt
known
alter
tertiari
structur
number
protein
therebi
could
interf
elisa
unfortun
could
determin
dttfree
sampl
avail
reanalysi
littl
publish
associ
inflammatori
phenotyp
sever
airway
obstruct
specif
virusinduc
asthma
exacerb
present
studi
sputum
eosinophil
feno
neg
correl
virusposit
patient
line
recent
experiment
studi
elimin
season
impact
inflammatori
marker
patient
recruit
four
season
howev
tabl
characterist
patient
infect
rhinoviru
rva
compar
patient
infect
rhinoviru
c
rvc
season
differ
inflammatori
marker
exacerb
observ
sensit
exposur
allergen
conjunct
viral
infect
shown
increas
risk
admiss
biolog
treatment
option
target
type
inflamm
report
reduct
exacerb
rate
yet
whether
predominantli
virusinduc
exacerb
prevent
nonvir
exacerb
unknown
possibl
inflammatori
phenotyp
express
stabl
diseas
repres
respons
develop
exacerb
regardless
trigger
prospect
studi
asthma
patient
phenotyp
stabl
diseas
follow
exacerb
requir
investig
mechan
increas
type
inflamm
might
neg
affect
cours
viru
infect
asthmat
clear
recent
mechanist
studi
suggest
type
inflammatori
pathway
may
lead
reduc
product
interferon
role
type
inflamm
relat
natur
occur
viral
infect
asthma
patient
much
less
examin
denling
colleagu
sampl
asthma
patient
symptom
cold
found
patient
went
develop
clinic
exacerb
character
higher
sputum
neutrophil
wherea
associ
eosinophil
feno
observ
howev
note
studi
aim
describ
sever
exacerb
potenti
associ
sputum
inflammatori
phenotyp
wark
colleagu
found
degranul
neutrophil
eosinophil
associ
longer
time
hospit
patient
admit
virusinduc
acut
asthma
present
studi
sputum
neutrophil
count
though
elev
virusposit
exacerb
compar
nonvir
exacerb
correl
sever
wheez
ill
report
children
infect
rvc
compar
rva
howev
establish
adult
present
studi
rvc
compris
rhinoviru
infect
e
proport
similar
report
wark
colleagu
found
differ
clinic
measur
sputum
inflammatori
phenotyp
patient
rvc
rva
note
patient
infect
rvc
higher
blood
eosinophil
exacerb
mediat
differ
ic
dose
howev
interpret
caution
type
marker
increas
conclus
found
type
inflamm
present
virusinduc
exacerb
extent
nonvir
exacerb
associ
lower
exacerb
unexpectedli
tslp
express
correl
neg
sputum
eosinophil
virusinduc
exacerb
suggest
pathway
includ
epitheli
cytokin
might
respons
drive
innat
pathway
lead
type
inflamm
acut
viru
induc
asthma
none
